Is active surveillance appropriate for men with favorable intermediate-risk prostate cancer?

In a paper in the first issue of the new journal JAMA Oncology, a group of US-based researchers argue that data from a series of > 5,000 patients treated with first-line brachytherapy suggest that men with favorable intermediate-risk prostate cancer are actually good candidates for active surveillance. … READ MORE …

When should therapeutic intervention take place for men on active surveillance?

The fact of the matter is that, as yet, we don’t have a good answer for this question, and it may be many years before we do. The reasons for this are numerous, but we are beginning to get some of the information we need to clarify the situation. … READ MORE …

Albertsen to discuss “contemporary recommendations” on AS at AUA annual meeting

In one of the more important lectures at the upcoming annual meeting of the American Urological Association, starting in Orlando in a couple of weeks’ time, Dr. Peter Albertsen will be reviewing contemporary recommendations on the practice of active surveillance (AS) for men with low- and very low-risk prostate cancer. … READ MORE …

One man’s route to active surveillance as a first-line management strategy

When CT learned that he had low-grade, organ-confined prostate cancer, he did not decide to get surgical or other therapeutic interventions immediately, based on the guidance of the first doctors he saw. Instead, he decided to actively monitor his disease and adjust his lifestyle habits with guidance from a team of specialists. … READ MORE …

How active should “active surveillance” really be? Are we being overly cautious?

There are a couple of brief but interesting new articles about active surveillance by Dr. Oliver Sartor and Laurence Klotz on the CancerNetwork.com web site this week. They deal with differing perceptions about the application of active surveillance. … READ MORE …

Life expectancy ≤ 10 years and the risks associated with treatment

According to Reuters, a new article, forthcoming on line in the Annals of Internal Medicine, tells us (not too surprisingly) that, “Older men with other illnesses may not live long enough to benefit from aggressive prostate cancer treatments, such as prostate removal or radiation, and they’d have to live with their side effects.” … READ MORE …

What happened early this morning at the GU Cancers Symposium

So … as a couple of readers have already realized … the sheer quantity of new and interesting data at the meeting is enormous, and your reporter is going to have to select what he tries to covers with care, ‘cos there’s no way to cover it all! … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,245 other followers